Understanding the Burden of Human Papillomavirus-associated Anal Cancers in the US

Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia 30341, USA.
Cancer (Impact Factor: 4.89). 11/2008; 113(10 Suppl):2892-900. DOI: 10.1002/cncr.23744
Source: PubMed

ABSTRACT Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed. The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas. Incidence rates were age-adjusted to the 2000 US standard population.
From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons. Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer. Women had a higher rate of SCC (1.5 per 100,000) than men (1.0). Whites and blacks had the highest incidence rate (1.3), whereas Asians/Pacific Islanders (API) had the lowest rate (0.3). Incidence rates of anal SCC increased 2.6% per year on average. The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%). API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively). Males had lower 5-year relative survival than females for all stages of disease.
Rates of anal SCC varied by sex, race, and ethnicity. A higher proportion of API were diagnosed at regional/distant stage. Men had lower 5-year survival rates than women. Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

Download full-text


Available from: Cyllene R Morris, Dec 17, 2013
22 Reads
  • Source
    • "Anal cancer is relatively less common than cervical cancer [1]. However, its incidence is rising annually in both genders in the general population [2]-[4]. Rates of anal cancer in at-risk groups, principally men who have sex with men (MSM) and persons infected by the human immunodeficiency virus (HIV), are considerably higher than those described in the healthy population [5]-[8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive-squamous-cell-cancer (ISCC) of the anal canal is an uncommon disease. Human papillo-mavirus (HPV) is the etiological agent of most of types of ISCC. The incidence of ISCC has been in-creasing in HIV-infected individuals, even after the introduction of highly active antiretroviral therapy. The aim of this study was to analyze biopsy specimens from patients diagnosed with ISCC at a tertiary hospital from 1983 to 2012 in order to detect HPV-DNA. Methods: Formaldehyde-fixed, paraffin-embedded specimens from patients with ISCC underwent HPV-DNA genotyping us-ing multiplex PCR assay. Results: A total of 31 cases were collected; 10 were HIV-infected (9 men, 1 woman) and 21 non-HIV-infected (11 men, 10 women). HPV infection was detected in 87.5% (7/8) of the HIV-infected patients (DNA from 2 biopsies was degraded) and 76.2% (16/21) of non-HIV-infected individuals. Multiple-type infections were only found in 28.6% (2/7) of the HIV-infected * Corresponding author. L. Darwich et al. 1156 patients (no multiple-type infections in non-HIV-infected individuals). The most prevalent type was HPV-16: 50% (4/8) in the HIV-infected group (57% [4/7] of the HPV-positive samples) and 66.7% (14/21) in the non-HIV-infected group (87.5% (14/16) of the HPV-positive samples). Re-markably, 37.5% (3/8) of the HIV-infected group had high-risk HPV types not included in the vac-cines (HPV-33, 51, 52, and 66) compared with 4.8% in the non-HIV-infected group (1/21, HPV-52). All cases of anal ISCC in HIV-infected patients were recorded in the highly active antiretroviral therapy era. Conclusion: HIV-infected patients presented anal ISCC with a higher proportion of high-risk HPV types not covered by the conventional vaccines than non-HIV-infected individuals.
    International Journal of Clinical Medicine 10/2014; 5(19):1155-1160. DOI:10.4236/ijcm.2014.519148
  • Source
    • "The incidence of anal cancer is increasing. In the UK, the incidence is estimated at approximately 1.5 per 100,000.1,2 Most of this increase is attributed to certain at-risk populations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of anal cancer is increasing. In the UK, the incidence is estimated at approximately 1.5 per 100,000. Most of this increase is attributed to certain at-risk populations. Persons who are human immunodeficiency virus (HIV)-positive and men who have sex with men (MSM), Organ transplant recipients, women with a history of cervical cancer, human papilloma virus (HPV), or cervical intraepithelial neoplasia (CIN) are known to have a greater risk for anal cancer. This paper will focus on HPV as a risk factor for anal intraepithelial neoplasia (AIN) and discusses the etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) of the anus.
    Clinical Medicine Insights: Oncology 09/2014; 8:113-9. DOI:10.4137/CMO.S13241
  • Source
    • "Cigarette smoking, receptive anal sex, lifetime number of sexual partners, pelvic radiation therapy, history of genital warts and/or previous neoplasms related to HPV infection, and immunosuppression conditions (transplantation HIV infection) are common risk factors. Particularly, ACC incidence rates are significantly higher in HIV-infected men and women than in HIV-uninfected ones, especially when considering men with homosexual habits [4] [5] [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The diagnostic performance of positron emission tomography using (18)F-fluorodeoxyglucose (FDG-PET) in detecting nodal involvement in patients with anal canal cancer (ACC) has been investigated by several studies with conflicting results. The aim of our study is to systematically review and meta-analyze published data about this topic. Methods: A comprehensive computer literature search of PubMed/MEDLINE, Scopus, and Embase databases was carried out on July 10 to find relevant articles concerning the diagnostic performance of FDG-PET in detecting locoregional nodal involvement in patients with ACC. No language restriction was used. Pooled diagnostic performance on a lesion-based analysis was calculated. Results: Seven retrospective and five prospective studies have been reviewed. Six studies allowed assessing pooled sensitivity; five studies allowed assessing pooled specificity. Sensitivity and specificity values of FDG-PET/CT on a lesion-based analysis ranged from 31 to 100% and from 53 to 98%, with pooled estimates of 56% (95% CI: 45-67%) and 90% (95% CI: 86-93%), respectively. Conclusions: Our meta-analysis demonstrates that FDG-PET is a specific diagnostic tool in detecting locoregional lymph node involvement in patients with ACC. Low sensitivity is a major concern; however, higher sensitivity could be reached combining FDG-PET with MR scan.
    The Scientific World Journal 02/2014; 2014:196068. DOI:10.1155/2014/196068 · 1.73 Impact Factor
Show more